Urology disorders pathophysiology, disease, symptom, diagnosis specific and treatment
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive reference for Urology Disorders covering pathophysiology, clinical features, diagnosis, and treatment — drawn from Campbell Walsh Wein Urology, Robbins & Kumar Basic Pathology, Sabiston Textbook of Surgery, Goldman-Cecil Medicine, and Quick Compendium of Clinical Pathology.
Urology Disorders: Comprehensive Reference
1. Benign Prostatic Hyperplasia (BPH)
Pathophysiology
BPH results from stromal and glandular proliferation originating in the periurethral transition zone. The primary hormonal driver is dihydrotestosterone (DHT), synthesized from testosterone by 5α-reductase type 2 in prostate stromal cells. DHT binds nuclear androgen receptors and upregulates growth factors that increase stromal cell proliferation and decrease epithelial cell apoptosis. With aging, declining testosterone combined with relatively stable or rising estrogen levels creates a permissive hormonal environment that synergizes with DHT to drive further growth. The enlarged gland compresses the urethra, increasing outflow resistance.
Symptoms
- Obstructive: hesitancy, weak stream, prolonged voiding, overflow dribbling, incomplete bladder emptying
- Irritative (storage): urinary frequency, nocturia, urgency, dysuria
- Recurrent UTIs from residual urine acting as a bacterial culture medium
- In severe cases: acute urinary retention, hydronephrosis
Diagnosis
- Clinical: IPSS (International Prostate Symptom Score) questionnaire
- Digital rectal exam (DRE) — enlarged, smooth, rubbery gland
- PSA (to exclude prostate cancer)
- Uroflowmetry (peak flow rate < 15 mL/s suggests obstruction)
- Post-void residual (PVR) ultrasound
- Transrectal ultrasound (TRUS) for gland volume
Treatment
| Category | Agent/Procedure | Mechanism |
|---|---|---|
| α-blockers | Tamsulosin, alfuzosin, doxazosin | Block α1-adrenergic receptors → relax smooth muscle |
| 5α-reductase inhibitors | Finasteride, dutasteride | Block DHT synthesis → reduce gland volume |
| Combination | α-blocker + 5α-RI | Additive benefit in large glands |
| Surgical | TURP, HIFU, laser, electrovaporization, radiofrequency ablation | Reserved for refractory cases |
2. Prostate Cancer (Adenocarcinoma)
Pathophysiology
The most common cancer in men (~21% of male cancers). Arises predominantly in the peripheral zone. Key molecular drivers: TMPRSS2-ETS fusion genes (most common acquired mutation) and activation of the PI3K/AKT pathway promoting tumor cell survival. Tumors are androgen-dependent. Risk factors: age > 50, African-American race, family history, high-fat diet.
Diagnosis
- PSA elevation (total PSA, PSA density, free:total PSA ratio)
- DRE: hard, irregular nodule
- TRUS-guided biopsy — 12-core template; histological grading by Gleason system (scale 1–5, sum ≥ 6)
- Risk stratification: PSA + DRE stage + Gleason sum
- Low risk: PSA < 10, Gleason ≤ 6, clinical stage < T2a
- High risk: PSA ≥ 20, Gleason 8–10, stage T3/T4
- Staging: Bone scan or PSMA PET-CT (bone mets); CT abdomen/pelvis (nodal mets)
- MRI prostate — increasingly used in diagnosis and treatment planning
Treatment
| Risk Level | Approach |
|---|---|
| Low risk | Active surveillance (PSA + DRE q3–6 months, serial biopsy q1–3 yrs) |
| Localized | Radical prostatectomy (open/laparoscopic/RALP) or definitive radiation therapy |
| Locally advanced | External beam radiation + androgen deprivation therapy (ADT) |
| Metastatic | ADT (surgical/medical castration); docetaxel or abiraterone for castration-resistant |
Radical prostatectomy (RALP): Robotic-assisted; nerve-sparing approach preserves erectile function. Bilateral pelvic lymph node dissection for Gleason ≥ 8.
3. Urolithiasis (Kidney Stones / Nephrolithiasis)
Stone Types & Pathophysiology
| Stone Type | Frequency | Promoters | Crystal Appearance |
|---|---|---|---|
| Calcium oxalate | 70% | Low urine volume, hypercalciuria, hyperoxaluria, low citrate | "Envelopes" |
| Calcium phosphate | ~5% | Alkaline urine, hypercalciuria | — |
| Struvite (triple phosphate) | ~10% | Urea-splitting organisms (Proteus mirabilis) — alkaline urine | "Coffin lids" → staghorn calculi |
| Uric acid | ~8% | Acidic urine, hyperuricosuria | Pleomorphic diamonds/squares |
| Cystine | ~1–2% | Cystinuria (autosomal recessive — defective COLA dibasic amino acid transport) | Hexagonal crystals |
Struvite stones account for 75% of staghorn calculi.
Symptoms
- Colicky flank pain radiating to groin/genitalia (renal colic)
- Hematuria (gross or microscopic)
- Nausea, vomiting
- Dysuria, urinary urgency (if near vesicoureteral junction)
- Fever/chills if associated infection (urological emergency)
Diagnosis
- Urinalysis: hematuria, crystals, pH (acid → uric acid; alkaline → struvite/phosphate)
- Non-contrast CT KUB — gold standard (detects all stone types except indinavir stones)
- Ultrasound (first-line in pregnancy/children)
- 24-hour urine collection: calcium, oxalate, citrate, uric acid, creatinine
- Serum: BMP, uric acid, PTH (if hypercalcemia)
Treatment
| Stone Size | Management |
|---|---|
| < 5 mm | Medical expulsive therapy (α-blockers — tamsulosin); hydration |
| 5–10 mm | Trial of passage ± α-blockers; consider intervention if persistent |
| > 10 mm | Extracorporeal shock wave lithotripsy (ESWL), ureteroscopy + laser lithotripsy, or percutaneous nephrolithotomy (PCNL) for large/staghorn stones |
Prevention (recurrence):
- High fluid intake (urine > 2 L/day)
- Calcium oxalate: low oxalate diet, thiazide diuretics (↓ calciuria), potassium citrate
- Uric acid: alkalize urine (potassium citrate), allopurinol
- Cystine: urinary alkalinization, D-penicillamine or tiopronin
4. Urinary Tract Infection (UTI)
Pathophysiology
Most UTIs result from ascent of periurethral flora into the bladder, predominantly gram-negative enteric organisms (E. coli accounts for ~80%). Virulence factors include bacterial fimbriae (adhesins), toxin production, and urease (especially Proteus, Klebsiella). Risk factors: female anatomy (short urethra), sexual activity, urinary tract anomalies (VUR, obstruction), instrumentation, diabetes, immunosuppression, post-renal transplant.
Classification
| Type | Definition |
|---|---|
| Cystitis (lower UTI) | Infection confined to bladder |
| Pyelonephritis (upper UTI) | Renal parenchymal involvement |
| Uncomplicated | Healthy non-pregnant woman, no structural abnormality |
| Complicated | Male, pregnancy, obstruction, catheter, immunosuppressed, renal transplant |
| Asymptomatic bacteriuria | Significant bacteriuria without symptoms |
Symptoms
- Cystitis: dysuria, urinary frequency/urgency, suprapubic pain, cloudy/malodorous urine
- Pyelonephritis: fever, chills, flank pain/CVA tenderness, nausea, vomiting ± cystitis symptoms
- Urosepsis: hemodynamic instability — requires emergent treatment
Diagnosis
- Urinalysis: pyuria (WBCs ≥ 10/hpf), nitrites (gram-negative bacteria), leukocyte esterase, bacteriuria
- Urine culture (gold standard): ≥ 10⁵ CFU/mL in midstream clean-catch (lower threshold in symptomatic patients)
- Blood cultures for pyelonephritis/urosepsis
- Imaging (US or CT) if obstruction, abscess, or complicated UTI suspected
Treatment
| Condition | First-line |
|---|---|
| Uncomplicated cystitis | Nitrofurantoin × 5 days, trimethoprim-sulfamethoxazole (TMP-SMX) × 3 days, or fosfomycin × 1 dose |
| Complicated UTI / pyelonephritis (outpatient) | Fluoroquinolone (ciprofloxacin/levofloxacin) × 7–14 days |
| Pyelonephritis (inpatient) | IV ampicillin-sulbactam, ceftriaxone, or piperacillin-tazobactam |
| Urosepsis | IV broad-spectrum; de-escalate per cultures; drain obstruction |
| Post-transplant UTI | TMP-SMX prophylaxis (also covers Pneumocystis); treat asymptomatic bacteriuria cautiously |
5. Urinary Incontinence & Overactive Bladder (OAB)
Types & Pathophysiology
| Type | Mechanism |
|---|---|
| Stress incontinence (SUI) | Urethral sphincter incompetence with increased intra-abdominal pressure (cough, sneeze, exercise); common in multiparous women |
| Urge incontinence (UUI) | Detrusor overactivity causing involuntary contraction before voiding |
| Mixed incontinence (MUI) | Combination of SUI + UUI |
| Overflow incontinence | Bladder overdistension from outflow obstruction (BPH) or detrusor underactivity; continuous dribbling |
| Functional incontinence | Cognitive/mobility impairment preventing timely toileting |
OAB is defined by urgency ± frequency ± nocturia ± urge incontinence, in the absence of UTI or obvious pathology. Prevalence increases with age; significantly impairs quality of life and sexual function (associated with depression — 3× higher incidence in incontinent patients).
Diagnosis
- History and voiding diary
- Urinalysis (exclude UTI)
- Urodynamic testing: cystometry, uroflowmetry, post-void residual
- Cystoscopy if hematuria/structural abnormality suspected
Treatment
Stress Incontinence:
- Pelvic floor (Kegel) exercises
- Midurethral sling surgery (TVT, TOT) — highly effective
- Bulking agents (periurethral injections)
Urgency Incontinence / OAB:
- Behavioral: bladder training, fluid/caffeine restriction, scheduled voiding
- Anticholinergics (1st-line): oxybutynin, tolterodine, solifenacin, darifenacin
- β3-agonist: mirabegron (fewer anticholinergic side effects)
- 3rd line: botulinum toxin injection into detrusor, sacral neuromodulation (InterStim), percutaneous tibial nerve stimulation (PTNS)
6. Bladder Cancer (Urothelial Carcinoma)
Pathophysiology
95–97% of bladder cancers in the US are urothelial (transitional cell) carcinomas. Two distinct pathways:
- Noninvasive papillary tumors (Ta, T1): gain-of-function mutations in FGFR3 → low-grade; progression uncommon (~20%)
- Carcinoma in situ (CIS): flat, high-grade lesion; TP53 and RB mutations → higher risk of muscle invasion
Risk factors: cigarette smoking (#1), aromatic amines (occupational), cyclophosphamide, prior pelvic radiation, schistosomiasis (S. haematobium → squamous cell carcinoma in endemic areas).
Symptoms
- Painless hematuria (gross or microscopic) — most common presenting symptom
- Irritative voiding symptoms (frequency, urgency, dysuria) with CIS
Diagnosis
- Urinalysis + urine cytology (sensitive for high-grade/CIS)
- Cystoscopy with biopsy — gold standard
- CT urography — upper tract evaluation
- TURBT (transurethral resection of bladder tumor): for staging and initial treatment
- Staging: T stage (depth of invasion) + N/M status
Treatment
| Stage | Treatment |
|---|---|
| Non-muscle invasive (Ta, T1) | TURBT + intravesical BCG (immunotherapy) or mitomycin C |
| CIS | TURBT + intravesical BCG × 6 weeks induction + maintenance |
| Muscle-invasive (T2+) | Neoadjuvant cisplatin-based chemotherapy + radical cystectomy (with neobladder/ileal conduit) or chemoradiation (bladder-sparing) |
| Metastatic | Platinum-based chemotherapy; checkpoint inhibitors (pembrolizumab, atezolizumab) |
7. Nephrotic Syndrome & Glomerulonephritis
Pathophysiology
Immunologic injury to glomeruli causes increased glomerular permeability → proteinuria. In nephrotic syndrome, protease filtration activates ENaC (epithelial sodium channel) in collecting tubules → sodium retention independent of aldosterone. In glomerulonephritis, reduced GFR also impairs salt excretion.
Nephrotic Syndrome (protein loss > 3.5 g/day):
- Hypoalbuminemia → edema, ascites, pleural effusions
- Hyperlipidemia and lipiduria (compensatory hepatic lipoprotein synthesis)
- Hypercoagulability (loss of anticoagulant proteins)
- Common causes: minimal change disease (children), FSGS, membranous nephropathy, diabetic nephropathy
Nephritic Syndrome (inflammatory):
- Hematuria, hypertension, oliguria, mild proteinuria
- Causes: IgA nephropathy (most common), post-streptococcal GN, ANCA-vasculitis, anti-GBM disease
Diagnosis
- Urinalysis: dysmorphic RBCs + RBC casts (nephritic); fatty casts/oval fat bodies (nephrotic)
- 24-hr urine protein or urine protein:creatinine ratio
- Serum BMP, albumin, lipids, complement (C3/C4)
- Serology: ANA, ANCA, anti-GBM, anti-streptolysin O (ASO), hepatitis B/C
- Renal biopsy — definitive diagnosis
Treatment
- Directed at underlying cause
- Negative sodium balance: loop diuretics (inhibit Na/K/2Cl cotransporter in thick ascending limb), dietary sodium restriction; ultrafiltration if refractory
- Immunosuppression per etiology (steroids, cyclophosphamide, rituximab, calcineurin inhibitors)
- ACE inhibitors/ARBs to reduce proteinuria and preserve renal function
8. Renal Cell Carcinoma (RCC)
Pathophysiology
Most common renal malignancy in adults. Arises from proximal tubular epithelium. Subtypes:
- Clear cell RCC (~75%): VHL gene mutation → HIF accumulation → VEGF/PDGF overexpression → angiogenesis
- Papillary RCC (~15%): MET mutations (type 1); fumarate hydratase (type 2)
- Chromophobe RCC (~5%): indolent
Risk factors: smoking, obesity, hypertension, hereditary syndromes (VHL, HLRCC, BHD).
Symptoms (Classic Triad — present in <10%)
- Flank pain, gross hematuria, palpable mass
- More commonly: incidental finding on imaging
- Paraneoplastic syndromes: polycythemia (EPO), hypercalcemia (PTHrP), Stauffer syndrome (non-metastatic hepatic dysfunction)
Diagnosis
- CT with contrast — gold standard; "clear cell" enhancement pattern
- MRI for IVC involvement
- Renal mass biopsy — selected cases
- Staging: TNM system
Treatment
| Stage | Treatment |
|---|---|
| Localized (T1–T2) | Partial or radical nephrectomy (open/laparoscopic/robotic) |
| Locally advanced (T3–T4) | Radical nephrectomy ± lymph node dissection |
| Metastatic | VEGFR-targeted therapy (sunitinib, pazopanib, cabozantinib) or mTOR inhibitors (everolimus) ± checkpoint inhibitors (nivolumab + ipilimumab) |
Quick Summary Table
| Disorder | Key Pathophysiology | Key Symptom | Key Diagnostic Test | First-line Treatment |
|---|---|---|---|---|
| BPH | DHT-driven stromal/glandular hyperplasia | Nocturia, weak stream | IPSS, uroflowmetry | α-blockers ± 5α-RI |
| Prostate Cancer | TMPRSS2-ETS fusion, PI3K/AKT | Often asymptomatic; elevated PSA | PSA + TRUS biopsy (Gleason) | Active surveillance or prostatectomy |
| Nephrolithiasis | Supersaturation → crystal precipitation | Renal colic + hematuria | Non-contrast CT | Expulsive therapy / lithotripsy |
| UTI | Ascending gram-negative colonization | Dysuria, frequency | UA + urine culture | TMP-SMX or nitrofurantoin |
| Urinary Incontinence | Sphincter incompetence / detrusor overactivity | Leakage with exertion / urgency | Urodynamics | Pelvic floor exercises / anticholinergics |
| Bladder Cancer | FGFR3 / TP53-RB mutations | Painless hematuria | Cystoscopy + biopsy | TURBT ± intravesical BCG |
| Nephrotic Syndrome | Glomerular permeability ↑ → protein loss | Edema, proteinuria > 3.5 g/d | Renal biopsy | Diuretics + cause-specific immunosuppression |
| RCC | VHL mutation → VEGF overexpression | Incidental / hematuria / flank pain | CT with contrast | Nephrectomy ± targeted therapy |
Sources: Campbell Walsh Wein Urology (9780323546423) • Robbins & Kumar Basic Pathology (9780323790185) • Sabiston Textbook of Surgery (9780443124341) • Goldman-Cecil Medicine (9780323930345) • Quick Compendium of Clinical Pathology (9780891896852)This reference covers the 8 major urology disorder categories in a structured format. Here's a brief orientation:
What's covered:
- BPH — DHT-driven hyperplasia; α-blockers and 5α-RI as medical management
- Prostate Cancer — Gleason grading, PSA-based screening, risk-stratified treatment from surveillance to RALP
- Nephrolithiasis — 5 stone types with distinct crystal appearance, risk factors, and stone-specific prevention
- UTI — Ascending infection pathophysiology; treatment by complexity (uncomplicated → urosepsis)
- Urinary Incontinence / OAB — 5 types distinguished by mechanism; anticholinergics/β3-agonists/neuromodulation
- Bladder Cancer — Two molecular pathways (FGFR3 papillary vs. TP53/RB CIS); TURBT + BCG as mainstay
- Nephrotic/Nephritic Syndrome — Glomerular permeability mechanisms; ENaC activation; biopsy for diagnosis
- Renal Cell Carcinoma — VHL-driven clear cell RCC; targeted VEGF/mTOR therapy for metastatic disease
Let me know if you'd like to go deeper into any specific disorder, add pediatric urology, erectile dysfunction, or infertility topics.
Yess specific disease, infertility and erticle dysfunction
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.